Mechanistic basis of increased susceptibility to nephrotoxicants in chronic liver disease

Massarweh, 2017, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Control, 24, 10.1177/1073274817729245

Paik, 2020, Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD, Hepatology, 72, 1605, 10.1002/hep.31173

Moon, 2020, Contemporary epidemiology of chronic liver disease and cirrhosis, Clin Gastroenterol Hepatol, 18, 2650, 10.1016/j.cgh.2019.07.060

Heimbach, 2021, Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical Industry perspective, Clin Pharmacol Ther, 110, 297, 10.1002/cpt.2125

Marie, 2022, Strategies to diagnose nonalcoholic steatohepatitis: A novel approach to take advantage of pharmacokinetic alterations, Drug Metab Dispos, 50, 492, 10.1124/dmd.121.000413

Dzierlenga, 2018, Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis, J Biochem Mol Toxicol, 32

Hardwick, 2011, Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease, Drug Metab Dispos, 39, 2395, 10.1124/dmd.111.041012

Vildhede, 2020, Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease, Clin Pharmacol Ther, 107, 1128, 10.1002/cpt.1699

Hardwick, 2014, Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis, Toxicol Sci, 142, 45, 10.1093/toxsci/kfu156

Lai, 2021, Pathologic diagnosis of nonalcoholic fatty liver disease, Arch Pathol Lab Med

Younossi, 2020, Epidemiology of chronic liver diseases in the USA in the past three decades, Gut, 69, 564, 10.1136/gutjnl-2019-318813

Wang, 2016, Transporter expression in liver Tissue from Subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics, Drug Metab Dispos, 44, 1752, 10.1124/dmd.116.071050

More, 2013, Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver, Drug Metab Dispos, 41, 1148, 10.1124/dmd.112.049676

Sebastiani, 2014, Chronic hepatitis C and liver fibrosis, World J Gastroenterol, 20, 11033, 10.3748/wjg.v20.i32.11033

Krens, 2019, Dose recommendations for anticancer drugs in patients with renal or hepatic impairment, Lancet Oncol, 20, e200, 10.1016/S1470-2045(19)30145-7

Calza, 2013, Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir, Scand J Infect Dis, 45, 147, 10.3109/00365548.2012.712213

Milburn, 2017, Renal effects of novel antiretroviral drugs, Nephrol Dial Transplant, 32, 434

Khan, 2019, Comparative effect of indomethacin (IndoM) on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in the kidney, small intestine and liver of rats, Toxicol Rep, 6, 389, 10.1016/j.toxrep.2019.04.010